Compare Rio Tinto (ADR) (RIO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rio Tinto (ADR) vs Travere Therapeutics Inc. Common Stock — how do they compare? Rio Tinto (ADR) trades at $88.22 (market cap $150.32B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Rio Tinto (ADR) is far larger — about 30.8× Travere Therapeutics Inc. Common Stock's market cap, and Rio Tinto (ADR) pays a 5% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rio Tinto (ADR) for 12 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RIO | TVTX | |
|---|---|---|
Market Cap | $150.32B | $4.88B |
Volume | 1,444,205 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $112.04 | $67.52 |
52-Week Low | $67.89 | $26.79 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $163.66B | $5.01B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rio Tinto (RIO) trades at $93.06, down 1.31% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company demonstrates strong profitability with 19.58% net income margin and 19.57% ROE, supported by recent quarterly earnings beats. Recent news highlights operational strength with 27% copper production growth at Oyu Tolgoi and maintained 2026 guidance.
The stock presents a compelling value opportunity with a 12.61 P/E ratio trading below the $103.13 consensus target. However, bearish technical momentum and legal risks from Madagascar contamination claims warrant caution. Analyst sentiment is mixed with 35% buy ratings versus 23% sell recommendations, suggesting balanced risk-reward for long-term investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rio Tinto (ADR)
Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
